Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data
Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (M
Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for refractory chronic spontaneous urticaria (CSU) for many years, but its efforts to find a su
Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improv
Germany’s Merck KGaA said this morning that the FDA has placed a partial clinical hold on its multiple sclerosis drug candidate evobrutinib, vying to become a new oral the
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year